{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:10:12Z","timestamp":1780726212224,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Eisai Co., Ltd."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>People of different ethnic or racial backgrounds may experience variations in pharmacokinetic and pharmacodynamic responses to drug therapies. Our post hoc analysis evaluated the efficacy, safety, and tolerability of perampanel in Asian and non\u2010Asian populations with refractory focal seizures with or without focal to bilateral tonic\u2010clonic (<jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content>) seizures. This analysis pooled data from 4 randomized, placebo\u2010controlled, phase\u20103 studies involving patients aged \u226512\u00a0years who have focal seizures with or without <jats:styled-content style=\"fixed-case\">FBTC<\/jats:styled-content> seizures. Patients were receiving 2, 4, 8, or 12\u00a0mg perampanel (or placebo) by the end of a 6\u2010week titration period and for a further 13\u00a0weeks during the maintenance phase. Efficacy endpoints included median percent change in seizure frequency per 28\u00a0days, and 50% and seizure\u2010freedom responder rates relative to baseline. The median percent change in seizure frequency per 28\u00a0days from baseline was significantly greater than placebo for perampanel 8 and 12\u00a0mg (\u221231.1% and \u221238.1% change, respectively; each <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.0001) in the Asian population, and for perampanel 4, 8, and 12\u00a0mg (\u221221.1% [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.0001], \u221226.3% [<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001], and \u221227.7% [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.0001] change, respectively) in the non\u2010Asian population. The 50% responder rate relative to baseline was significantly greater than placebo for perampanel 8 and 12\u00a0mg (40.1% and 43.8%, respectively; each <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.0001) in the Asian population, and for perampanel 4, 8, and 12\u00a0mg (29.4% [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.0002], 32.8% [<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.0001] and 34.5% [<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.0001]), respectively, in the non\u2010Asian population. Seizure\u2010freedom rate among all patients was 4.9%\u201011.7% for perampanel 2, 4, 8, and 12\u00a0mg. The most frequently reported treatment\u2010emergent adverse events (<jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s) across both populations were dizziness, somnolence, irritability, headache, and fatigue. The most common psychiatric <jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s were aggression and irritability. Perampanel demonstrated a favorable and similar risk\u2010benefit profile in both Asian and non\u2010Asian populations with refractory focal seizures.<\/jats:p>","DOI":"10.1111\/epi.14642","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T10:00:13Z","timestamp":1552557613000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy, safety, and tolerability of perampanel in Asian and non\u2010Asian patients with epilepsy"],"prefix":"10.1111","volume":"60","author":[{"given":"Jing\u2010Jane","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Neurology National Cheng Kung University Hospital and School of Medicine National Cheng Kung University Tainan City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Epilepsy, Movement Disorders and Physiology Kyoto University Graduate School of Medicine Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology Samsung Medical Center Samsung Biomedical Research Institute Samsung Medical Center and Samsung Advanced Institute for Health Sciences &amp; Technology Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surachai","family":"Likasitwattanakul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Faculty of Medicine Mahidol University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[{"name":"Eisai Singapore Pte. Ltd. Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70127-8"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization.Epilepsy 2018: Rates of Disease. Available at:http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy. Accessed August 16 2018."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.141"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903427969"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200410000-00012"},{"key":"e_1_2_9_8_1","unstructured":"Food and Drug Administration.Fycompa\u00aePrescribing Information 2018. Available at:https:\/\/www.fycompa.com\/-\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf. Accessed October 03 2018."},{"key":"e_1_2_9_9_1","unstructured":"European Medicines Agency.Fycompa\u00aeAnnex I: Summary of Product Characteristics. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002434\/WC500130815.pdf. Accessed August 30 2018."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12883"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12865"},{"key":"e_1_2_9_15_1","unstructured":"MedDRA.MedDRA queries Introductory Guide for Standardised MedDRA Queries (SMQs) Version 16.0 2013. Available at:https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_16_0_english.pdf. Accessed September 10 2018."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12874"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00321.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900208"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.08.001"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00372.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.12.005"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd6170"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2012.03.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02729.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13212"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03605.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001558"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12529"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:51:25Z","timestamp":1694407885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/epi.14642"],"URL":"https:\/\/doi.org\/10.1111\/epi.14642","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2017-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}